---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-026112"
form_type: "8-K"
ticker: "EMMA"
cik: "0000822370"
company_name: "Emmaus Life Sciences, Inc."
filed_at: "2022-05-13T23:59:59+00:00"
generated_at: "2026-06-25T17:21:13.321035+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Emmaus Q1 revenue drops 40% to $3.2M; cash falls to $0.8M; working capital insufficient

## Summary
- Net revenue $3.2M, down from $5.3M YoY; sell-through improved but overstocking by distributors hit revenue.
- Net loss to common stockholders $1.5M ($0.03/share), improved from $8.4M loss ($0.17/share) in Q1 2021.
- Loss from operations widened to $3.1M from $1.6M; operating expenses reduced to $5.3M from $6.5M.
- Cash $0.8M at March 31, 2022; management says working capital insufficient for 2022 without additional financing.
- Launched Endari telehealth program; Florida Medicaid added Endari to preferred drug list; received UAE marketing authorization.

## SEC filing metadata
- accession: 0001213900-22-026112
- form_type: 8-K
- ticker: EMMA
- cik: 0000822370
- company_name: Emmaus Life Sciences, Inc.
- filed_at: 2022-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/822370/000121390022026112/0001213900-22-026112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/822370/000121390022026112/ea159763-8k_emmaus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-026112
- JSON: https://secwatch.observer/filing/0001213900-22-026112.json
- Plain text: https://secwatch.observer/filing/0001213900-22-026112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.